EP4157284A1 - Use of nmn to reduce immunodepression and immunosenescence - Google Patents
Use of nmn to reduce immunodepression and immunosenescenceInfo
- Publication number
- EP4157284A1 EP4157284A1 EP21728902.4A EP21728902A EP4157284A1 EP 4157284 A1 EP4157284 A1 EP 4157284A1 EP 21728902 A EP21728902 A EP 21728902A EP 4157284 A1 EP4157284 A1 EP 4157284A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- aryl
- nmn
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 claims abstract description 78
- 150000003839 salts Chemical class 0.000 claims abstract description 71
- 239000000203 mixture Substances 0.000 claims abstract description 26
- -1 cyano, hydroxyl Chemical group 0.000 claims description 129
- 150000001875 compounds Chemical class 0.000 claims description 107
- 125000000217 alkyl group Chemical group 0.000 claims description 73
- 125000003118 aryl group Chemical group 0.000 claims description 58
- 229960005486 vaccine Drugs 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 230000001506 immunosuppresive effect Effects 0.000 claims description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 34
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 33
- 210000000952 spleen Anatomy 0.000 claims description 33
- 206010062016 Immunosuppression Diseases 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 29
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 229930182852 proteinogenic amino acid Natural products 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 14
- 230000009467 reduction Effects 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- DAYLJWODMCOQEW-CDLYGTGVSA-N alpha-Nicotinamide mononucleotide Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-CDLYGTGVSA-N 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004001 thioalkyl group Chemical group 0.000 claims description 10
- 241000233866 Fungi Species 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 9
- 150000004677 hydrates Chemical class 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 244000045947 parasite Species 0.000 claims description 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 7
- 241000709661 Enterovirus Species 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 6
- 125000004437 phosphorous atom Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 230000002992 thymic effect Effects 0.000 claims description 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 241000351643 Metapneumovirus Species 0.000 claims description 4
- 241000711902 Pneumovirus Species 0.000 claims description 4
- 241001113283 Respirovirus Species 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000712891 Arenavirus Species 0.000 claims description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 3
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 3
- 241001468007 Erbovirus Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 241000035314 Henipavirus Species 0.000 claims description 3
- 241000709715 Hepatovirus Species 0.000 claims description 3
- 241000712045 Morbillivirus Species 0.000 claims description 3
- 241001263478 Norovirus Species 0.000 claims description 3
- 241000713112 Orthobunyavirus Species 0.000 claims description 3
- 241001631646 Papillomaviridae Species 0.000 claims description 3
- 241000713137 Phlebovirus Species 0.000 claims description 3
- 241000702670 Rotavirus Species 0.000 claims description 3
- 241000710801 Rubivirus Species 0.000 claims description 3
- 241001533467 Rubulavirus Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 241000701067 Varicellovirus Species 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 230000005847 immunogenicity Effects 0.000 claims description 3
- 229940031551 inactivated vaccine Drugs 0.000 claims description 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 101100240519 Caenorhabditis elegans nhr-13 gene Proteins 0.000 claims description 2
- 241000711557 Hepacivirus Species 0.000 claims description 2
- 241000710778 Pestivirus Species 0.000 claims description 2
- 229940031348 multivalent vaccine Drugs 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 241000004176 Alphacoronavirus Species 0.000 claims 1
- 125000006519 CCH3 Chemical group 0.000 claims 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 abstract description 43
- 230000028993 immune response Effects 0.000 abstract description 2
- 238000002255 vaccination Methods 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 59
- 238000000034 method Methods 0.000 description 24
- 210000001541 thymus gland Anatomy 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 210000001185 bone marrow Anatomy 0.000 description 16
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 12
- 229910019142 PO4 Inorganic materials 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 12
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 12
- 239000010452 phosphate Substances 0.000 description 12
- 125000003226 pyrazolyl group Chemical group 0.000 description 12
- 238000001959 radiotherapy Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 230000000340 anti-metabolite Effects 0.000 description 11
- 229940100197 antimetabolite Drugs 0.000 description 11
- 239000002256 antimetabolite Substances 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 229950006238 nadide Drugs 0.000 description 11
- 239000011618 nicotinamide riboside Substances 0.000 description 11
- 229940045799 anthracyclines and related substance Drugs 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 102000000589 Interleukin-1 Human genes 0.000 description 9
- 108010002352 Interleukin-1 Proteins 0.000 description 9
- 229940100198 alkylating agent Drugs 0.000 description 9
- 239000002168 alkylating agent Substances 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 235000020956 nicotinamide riboside Nutrition 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 125000003386 piperidinyl group Chemical group 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 150000001887 cortisones Chemical class 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 208000004235 neutropenia Diseases 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 6
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 6
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 239000002841 Lewis acid Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 229940076144 interleukin-10 Drugs 0.000 description 6
- 150000007517 lewis acids Chemical class 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 241000186359 Mycobacterium Species 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- 229960002170 azathioprine Drugs 0.000 description 5
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- WVPKAWVFTPWPDB-UHFFFAOYSA-M dichlorophosphinate Chemical compound [O-]P(Cl)(Cl)=O WVPKAWVFTPWPDB-UHFFFAOYSA-M 0.000 description 5
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 229960000390 fludarabine Drugs 0.000 description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 5
- 208000014951 hematologic disease Diseases 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 5
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 5
- 229960004866 mycophenolate mofetil Drugs 0.000 description 5
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 5
- 229960000951 mycophenolic acid Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 5
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 4
- 208000008190 Agammaglobulinemia Diseases 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 206010010099 Combined immunodeficiency Diseases 0.000 description 4
- 108010069112 Complement System Proteins Proteins 0.000 description 4
- 102000000989 Complement System Proteins Human genes 0.000 description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 201000008962 Nezelof syndrome Diseases 0.000 description 4
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 4
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229940009098 aspartate Drugs 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 208000016097 disease of metabolism Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 description 4
- 238000002650 immunosuppressive therapy Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 150000002972 pentoses Chemical class 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 4
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 4
- 125000005039 triarylmethyl group Chemical group 0.000 description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- 241000223836 Babesia Species 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 3
- 241000588807 Bordetella Species 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 241000223924 Eimeria Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 241000222722 Leishmania <genus> Species 0.000 description 3
- 206010025327 Lymphopenia Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241000242678 Schistosoma Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 241000223996 Toxoplasma Species 0.000 description 3
- 241000223238 Trichophyton Species 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 230000001494 anti-thymocyte effect Effects 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 201000008680 babesiosis Diseases 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 229960003840 cortivazol Drugs 0.000 description 3
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229960003901 dacarbazine Drugs 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229960002011 fludrocortisone Drugs 0.000 description 3
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000018706 hematopoietic system disease Diseases 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000138 intercalating agent Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 231100001023 lymphopenia Toxicity 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- 229960004961 mechlorethamine Drugs 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229960004584 methylprednisolone Drugs 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 3
- 229960000624 procarbazine Drugs 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 229960004964 temozolomide Drugs 0.000 description 3
- 229960005294 triamcinolone Drugs 0.000 description 3
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 3
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 2
- MAKBMGXNXXXBFE-TURQNECASA-N 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MAKBMGXNXXXBFE-TURQNECASA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010053622 Asplenia Diseases 0.000 description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 2
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000016917 Complement C1 Human genes 0.000 description 2
- 108010028774 Complement C1 Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 201000007151 Good syndrome Diseases 0.000 description 2
- 206010019860 Hereditary angioedema Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 208000009388 Job Syndrome Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108700017801 Purine Nucleoside Phosphorylase Deficiency Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 201000001322 T cell deficiency Diseases 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 2
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 2
- 206010000596 acrodermatitis enteropathica Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229940067621 aminobutyrate Drugs 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000008560 complement component 3 deficiency Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000009547 development abnormality Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000003918 fraction a Anatomy 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 210000004987 germinal b lymphocyte Anatomy 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 210000003297 immature b lymphocyte Anatomy 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000000638 myeloperoxidase deficiency Diseases 0.000 description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229960001221 pirarubicin Drugs 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 208000001917 purine nucleoside phosphorylase deficiency Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 2
- 229940055619 selenocysteine Drugs 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000010911 splenectomy Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940098466 sublingual tablet Drugs 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- ZRHONLCTYUYMIQ-TZFCGSKZSA-N (2Z,4E)-2-aminomuconic acid Chemical compound OC(=O)C(/N)=C/C=C/C(O)=O ZRHONLCTYUYMIQ-TZFCGSKZSA-N 0.000 description 1
- IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 1
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- 125000002152 1H-pyrrolizinyl group Chemical group C1(C=CN2C=CC=C12)* 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical class OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- ZRHONLCTYUYMIQ-CCAGOZQPSA-N 2-Aminomuconic acid Natural products O=C(O)/C(/N)=C/C=C\C(=O)O ZRHONLCTYUYMIQ-CCAGOZQPSA-N 0.000 description 1
- KUQRLZZWFINMDP-BGNLRFAXSA-N 2-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KUQRLZZWFINMDP-BGNLRFAXSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical class CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000006087 2-oxopyrrolodinyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ADVPTQAUNPRNPO-REOHCLBHSA-N 3-sulfino-L-alanine Chemical compound OC(=O)[C@@H](N)C[S@@](O)=O ADVPTQAUNPRNPO-REOHCLBHSA-N 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N 4-thiomorpholin-4-ylsulfinylthiomorpholine Chemical compound C1CSCCN1S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N 4-thiomorpholin-4-ylsulfonylthiomorpholine Chemical compound C1CSCCN1S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108700009273 Complement Component 6 Deficiency Proteins 0.000 description 1
- 108700037244 Complement Component 7 Deficiency Proteins 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 229930195713 D-glutamate Natural products 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 229930182819 D-leucine Natural products 0.000 description 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
- 229930182831 D-valine Natural products 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- ADVPTQAUNPRNPO-UHFFFAOYSA-N alpha-amino-beta-sulfino-propionic acid Natural products OC(=O)C(N)CS(O)=O ADVPTQAUNPRNPO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- KDZOASGQNOPSCU-UHFFFAOYSA-N argininosuccinate Chemical compound OC(=O)C(N)CCCN=C(N)NC(C(O)=O)CC(O)=O KDZOASGQNOPSCU-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical class C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000007380 inflammaging Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-M orotate Chemical compound [O-]C(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-M 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011734 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000004263 tetrahydroisoquinolin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])C2=C([H])C([H])=C([H])C([H])=C2C1([H])* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
- 229910052725 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Definitions
- the present invention relates to the use of NMN, one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, for the treatment and prevention of immunosuppression, and more particularly immunosenescence.
- the present invention also relates to compositions comprising NMN, one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, for the treatment and prevention of immunosuppression, and more particularly. immunosenescence.
- Immunosuppression is the phenomenon of reduction of the primary immune response of an individual.
- an immunocompromised subject may not exhibit a satisfactory immune defense response to bacterial and viral infections.
- Immunosuppression can be either hereditary, or caused by immunosuppressive therapy, or caused by a disease such as cancer, HIV infection, or an individual's aging.
- Immunosenescence is a form of immunodepression and is the phenomenon of marked loss of efficiency of the immune system, whether it is innate and / or adaptive immunity, induced by the aging of the individual. Immunosenescence helps to increase the sensitivity of the elderly to viral and bacterial infections in particular. There are many causes of immunosenescence. Immunosenescence can be caused by old age, disease such as cancer or osteoporosis, smoking, diet, pollution, and other environmental factors.
- Immunosenescence affects various types of cells in the bone marrow and thymus, mature lymphocytes in peripheral blood and secondary lymphatic organs, as well as elements of the innate immune system.
- the immune system can be divided into an innate part, composed mainly of monocytes, natural killer cells (NK) and dendritic cells (DC), and an adaptive part, represented by B and T lymphocytes. Innate immunity is better preserved, while more serious, often harmful and age-dependent changes occur in the adaptive immune system.
- immunosenescence results in less efficient lymphocyte production, activation and reactivity. This results in increased susceptibility to inflammatory reactions and autoimmunity and decreased reactions to infections, tumors and vaccinations.
- the immunological modifications induced by aging result in the appearance of a chronic low-level inflammation referred to in English by the term “inflammaging”.
- This inflammation is associated with a release of large quantities of pro-inflammatory agents and proteases in the tissues and in particular in the mucous membranes, inducing low-level inflammation.
- Chronic low-level inflammation can be defined as inflammation showing no classic clinical signs of inflammation namely redness, swelling, warmth, pain.
- markers of inflammation such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-a), the receptor antagonist to interleukin 1 (IL-IRa) , C-reactive protein (CRP).
- IL-6 interleukin-6
- TNF-a tumor necrosis factor alpha
- IL-IRa the receptor antagonist to interleukin 1
- CRP C-reactive protein
- NNN nicotinamide mononucleotide
- the present invention relates to nicotinamide mononucleotide (NMN), one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, for in the prevention and / or treatment of immunosenescence .
- NNN nicotinamide mononucleotide
- the NMN derivative can be chosen from alpha nicotinamide mononucleotide (a-NMN), dihydronicotinamide mononucleotide (denoted NMN-H), the compound of formula (I):
- R 1 is selected from H, azido, cyano, C 1 -C 6 alkyl, thio-C 1 -C 6 alkyl, C 1 -C 8 heteroalkyl and OR; wherein R is selected from F1 and C1-C8 alkyl;
- R2, R3, R4 and R 5 are selected independently of one another from Fl, halogen, azido, cyano, hydroxyl, C 1 -C 12 alkylthio-C 1 -C 12 heteroalkyl, C 1 -C 12 , C 1 -C 12 haloalkyl and OR; wherein R is selected from F1, C 1 -C 12 alkyl, C (0) (Ci-Ci 2 ) alkyl, C (0) NFI (Ci-Ci 2 ) alkyl, C (0) 0 (Ci-Ci 2 ) alkyl, C (0) aryl, C (0) (Ci-Ci 2 ) alkyl aryl, C (0) NFI (Ci-Ci 2 ) alkyl aryl, C (0) 0 (Ci-Ci 2 ) alkyl aryl and C (0) CFI RAANFI2; wherein RAA is a side chain selected from a proteinogenic amino acid;
- R 6 is selected from F1, azido, cyano, C1-Cg alkyl, C1-Cg thio-alkyl, C1-Cg heteroalkyl and OR; wherein R is selected from F1 and C1-Cgalkyl;
- R 7 is chosen from in which n is an integer equal to 1 or 3; in which
- Rg and Rio are independently selected from each other from OFI, ORn, NFIR13, NR13R14, alkyl, Ci-Cg alkenyl, C2-C6, alkynyl a C 2-C6, a cycloalkyl C 3 -C 10 , a C 5 -C 12 aryl, (Ci- Cg) alkyl aryl, (Ci-Cg) aryl alkyl, (Ci-Cg) heteroalkyl, (Ci-Cg) heterocycloalkyl, a heteroaryl and NHCHR A R A ' C (0) RI 2 ; in which :
- Ru is chosen from a C1-Cioalkyl, C 3 -Ciocycloalkyl, C 5 -Cig aryl, C 1 -C 10 alkylaryl, C 5 - C 12 substituted aryl, C 1 -C 10 heteroalkyl, C 3 -C 10 heterocycloalkyl, C 1 -C 10 haloalkyl, a heteroaryl, - (CH 2 ) nC (0) (Ci-Ci 5 ) alkyl, - (CH 2 ) nOC (0) (Ci-Ci 5 ) alkyl, - (CH 2 ) nOC (0) 0 (Ci-Ci 5 ) alkyl, - (CH 2 ) favorSC (0) (Ci-Ci 5 ) alkyl, - (CFl 2 ) nC (0) 0 (Ci-Ci 5 ) alkyl and - ( CFl 2) nC (0) 0 (Ci-C
- R is selected from H, (Cs-Ce) aryl and (Cs-Ce) heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with halogen, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy and cyano;
- Rg and Rio together with the phosphorus atoms to which they are attached form a 6-membered ring in which -Rg-Rio- represents -O-CH 2 -CH 2 -CHR-O-; in which R is chosen from H, a (Cs-Ce) aryl and (C 5 -Ce) heteroaryl group, in which said aryl or heteroaryl groups are optionally substituted by a halogen, trifluoromethyl, a (Ci-C 6 ) alkyl, a (Ci-C 6 ) alkoxy and cyano;
- Rg is selected from H, OR, NHR 13 , NR 13 R 14 , NH-NHR 13 , SH, CN, N 3 and halogen; wherein R 13 and R 14 are independently selected from H, (C1-Cg) alkyl and (C1-Cg) alkyl aryl;
- Y is selected from CH, CH 2 , C (CH 3 and CCH 3 ;
- LLL / ⁇ represents the alpha or beta anomer depending on the position of Ri or one of its stereoisomers, one of its salts, one of its hydrates, one of its solvates or one of its crystals or the compound of formula (Ia):
- R'i and R'13 are independently selected from F1, azido, cyano, C1-C8 alkyl, C1-C8 thioalkyl, C1-C8 heteroalkyl, and OR, wherein R is selected from F1 and a C1-C8 alkyl,
- R '2, R' 3, R '4, R' 5, R '9, R' 10, R '11, R' 12 are independently selected from H, halogen, azido, cyano, hydroxyl, a C 1 -C 12 thioalkyl a C 1 -C 12 alkyl, hetero-alkyl C -C 12, haloalkyl Cl-Cl 2 and OR wherein R may be selected from H, alkyl C 1 -C 12 , a C (0) (C 1 -C 12 ) alkyl, a C (0) NFI (Ci-Ci 2 ) alkyl, a C (0) 0 (Ci-Ci 2 ) alkyl, a C ( O) aryl, a C (0) (C 1 -C 12 ) aryl, a C (0) NFI (Ci-Ci 2 ) alkyl aryl, a C (0) 0 (Ci-Ci 2 ) alkyl aryl or
- R '6 and R'g are independently selected from H, azido, cyano, C1-C8 alkyl and OR, wherein R is selected from F1 and C1-C8 alkyl;
- R '7 and R' 14 are independently selected from F1, OR, NFIR, NRR ', N FH-NFH R, SFH, CN, N3 and halogen, wherein R and R' are independently selected from F1 and (Ci -Cg) alkyl aryl;
- Y'i and Y ' 2 are independently selected from CFI, CFI 2 , C (CFl 3 ) 2 or CCFI 3 ;
- M ' is chosen from F1 or a suitable counterion; represents a single or double bond depending on Y'i and Y'2; and -vwv represents an alpha or beta anomer depending on the position of R'I and R'13; and their combinations.
- the pharmaceutically acceptable derivative is the compound of formula (I).
- X represents oxygen
- Ri and R 6 each represent, independently of one another, a hydrogen.
- R 2 , R 3 , R 4 and R 5 each represent, independently of one another, a hydrogen or an OH.
- Y represents a CH.
- Y represents a CH2.
- R 7 represents hydrogen
- R 7 represents P (0) (OH) 2 .
- X represents oxygen
- R 1 and R 6 each independently represents hydrogen; and or
- R 2 , R 3 , R 4 and R 5 each independently represents hydrogen or R 2 , R 3 , R 4 and R 5 independently represents OH; and or
- Y represents CH or CH2;
- R 7 represents P (0) RgRio, in which Rg and Rio are independently selected from OH, ORn, NHR13, NR13R14, C1-Cgalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-Ciocycloalkyl, C5-C12 aryl, Ci -Cg aryl alkyl, Ci-Cg alkyl aryl, Ci-Cgheteroalkyle, Ci-Cgheterocycloalkyl, heteroaryl and NHCRARA C (0) RI2.
- the compound of the invention is chosen from the compounds of formula I-A to I-J:
- the pharmaceutically acceptable derivative is the compound of formula (Ia).
- C ⁇ and X'2 each independently represent oxygen.
- R'7 and R'14 each independently represent an NH2.
- R'I and / or R'13 each independently represent hydrogen.
- R'6 and / or R'8 each independently represent hydrogen.
- R'2, R'3, R'4 , R'5, R'9, R'10, R'11 and R'12 each independently represent hydrogen.
- R'2, R'3, R'4 , R'5, R'9, R'10, R'11 and R'12 each independently represent an OH.
- Y'1 and Y'2 each independently represent a CH.
- Y'1 and Y'2 each independently represent a CH2.
- the compound according to the invention is chosen from the compounds of formula la-A to la-l:
- the pharmaceutically acceptable derivative is NMN-H:
- the pharmaceutically acceptable precursor is nicotinamide riboside (denoted NR):
- the nicotinamide mononucleotide (NMN), one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts can be administered orally, ocular, sublingual, parenteral, transcutaneous, vaginal, epidural, intravesical, rectal or inhalation.
- the nicotinamide mononucleotide (NMN), one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts can be administered orally or parenterally, preferably orally.
- the parenteral route can be chosen from among the intraarterial route, the intravenous route, the intramuscular route, the subcutaneous route, the intraperitoneal route, more preferably the intravenous route.
- the nicotinamide mononucleotide (NMN), one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts can be in the form of a tablet, a capsule, or '' a sachet, a granule, a soft capsule, a pellet, a lyophilisate, a suspension, a gel, a syrup, a solution, an emulsion water / oil, oil / water emulsion, oil, cream, milk, spray, ointment, ampoule, suppository, eye drops , vaginal egg, vaginal capsule, liquid for inhalation, dry powder inhaler, pressurized metered valve inhaler, powder.
- the nicotinamide mononucleotide (NMN), one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts is in the form of a powder, a suspension, or a solution, a water / oil emulsion or an oil / water emulsion.
- the NMN can be used in an amount of between 0.01 mg / kg / day and 500 mg / kg / day, preferably between 0.1 mg / kg / day and 350 mg / kg / day, more preferably between 0.5 and 100 mg / kg / day, even more preferably 5 mg / kg / day at 50 mg / kg / day.
- the NMN can be administered to a mammal, preferably a human.
- the NMN, one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts can be administered to a human aged at least 45 years, preferably of 'at least 50 years, preferably at least 55 years, preferably at least 60 years, preferably at least 65 years, more preferably at least 70 years, still more preferably d at least 75 years of age for the treatment of immunosenescence.
- the NMN, one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts can be administered to a human aged at least 15 years, preferably of at least 20 years, more preferably at least 25 years, more preferably at least 30 years, even more preferably at least 35 years for the prevention of immunosenescence.
- the NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, can be administered in combination with at least one other therapeutic agent.
- the at least one other therapeutic agent is a vaccine which can be chosen from live attenuated vaccines, inactivated vaccines, multivalent vaccines or combination vaccines.
- said vaccine is chosen from a vaccine against a virus, a bacterium, a parasite or a yeast and / or a fungus, or their combinations.
- said vaccine is a vaccine against a virus selected from Influenzavirus, Coronavirus, Respirovirus, Pneumovirus, Metapneumovirus, Adenovirus, Enterovirus, Rhinovirus, Hepatovirus, Erbovirus, Aphtovirus, Norovirus, Alphavirus, Rubivirus, Flavivirus, Hepivirus, Pestivirus, Ebola, Morbillivirus, Rubulavirus, Henipavirus, Arenavirus, Orthobunyavirus, Phlebovirus, Rotavirus, Simplexvirus, Varicellovirus, Papillomavirus, Cytomegalovirus or their combinations.
- a virus selected from Influenzavirus, Coronavirus, Respirovirus, Pneumovirus, Metapneumovirus, Adenovirus, Enterovirus, Rhinovirus, Hepatovirus, Erbovirus, Aphtovirus, Norovirus, Alphavirus, Rubivirus, Flavivirus, Hepivirus, Pestivirus, Ebola, Morbillivirus, Rub
- the vaccine against the virus is chosen from Influenza irus, Coronavirus, Rhinovirus, Respirovirus, Pneumovirus or Metapneumovirus, more preferably Influenzavirus.
- said vaccine is a vaccine against a bacterium selected from Pneumococcus, Streptococcus, Corynebacterium, Clostridium, Mycobacterium, Bordetella, Neisseiri and their combinations.
- the Mycobacterium is Mycobacterium tuberculosis.
- said Nesseiria is Neisseria meningitis.
- said vaccine is a vaccine against a parasite selected from Schistosoma, Leishmania, Babesia and their combinations.
- said vaccine is a vaccine against a yeast and / or a fungus selected from Trichophyton, Toxoplasma, Eimeria, Candida and their combinations.
- the at least one therapeutic agent is radiotherapy, chemotherapy or combinations thereof.
- the radiotherapy can be chosen from X or gamma irradiation.
- the chemotherapy can be chosen from an antimetabolite, an alkylating agent, a topoisomerase inhibitor, an anthracycline, and their combinations.
- the alkylating agent can be chosen from dacarbazine, temozolomide, streptozocin, cyclophosphamide, ifofosfamide, melphalan, procarbazine, busulfan, triphosphoramide, hexamethylmelamine, chlormethine, salts platinum such as cisplatin, carboplatin, oxaliplatin and combinations thereof.
- the at least one therapeutic agent is an immunosuppressive treatment.
- the immunosuppressive treatment can be chosen from an anti-metabolite, a TNF alpha inhibitor, an interleukin-1 (IL1) inhibitor, a cortisone derivative, a calcineurin inhibitor, rapamycin, a anti-CD25 antibodies, lymphoablative therapy and combinations thereof.
- IL1 interleukin-1
- cortisone derivative a cortisone derivative
- calcineurin inhibitor a calcineurin inhibitor
- rapamycin a anti-CD25 antibodies
- lymphoablative therapy lymphoablative therapy and combinations thereof.
- the antimetabolite can be chosen from azathioprine, methotrexate, mycophenolic acid, mycophenolate mofetil, fludarabine, and their combinations.
- the cortisone derivative is chosen from betamethasone, ciprofloxacin, cortivazol, dexamethasone, fludrocortisone, methylprednisolone, prednisolone, triamcinolone and their combinations.
- the calcineurin inhibitor can be chosen from cyclosporine, tacrolimus and their combinations.
- the lymphoablative treatment can be chosen from chemotherapy, radiotherapy, an alkylating agent, an intercalator, an anthracycline, anti-thymocyte globulins, a CD52 monoclonal antibody, an OKT3 monoclonal antibody and their combinations.
- the NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, can be administered concomitantly with the administration of at least one additional therapeutic agent.
- the NMN can be administered for a period of between 10 and 60 days, preferably between 14 and 42 days, more preferably for about 30 days prior to the administration of at least one additional therapeutic agent.
- the immunosuppression can be a primary immunosuppression or a secondary immunosuppression.
- the primary immunosuppression is of hereditary origin and can be chosen from a predominantly humoral primary immunosuppression, a predominantly cellular primary immunosuppression, a combined deficiency, a deficiency in complement proteins, or a deficiency of the. macrophage and polynucelar activity.
- the predominantly humoral primary immunosuppression can be chosen from agammaglobulinemia linked to sex or Bruton's disease, common hypogammaglobulinemia of variable expression or a selective deficit in immunoglobulins such as a deficiency in IgA, IgD , IgG and / or IgM.
- the predominantly cellular primary immunosuppression can be chosen from 22qll microdeletion or Di George's syndrome, Hong and Good's syndrome, Nezelof's syndrome, purine nucleoside phosphorylase deficiency, isolated T lymphocyte deficiency.
- the combined deficit can be chosen from the severe combined immunodeficiency by adenosine deaminase deficiency. denuded lymphocyte syndrome, congenital amegakaryocytosis with developmental abnormality of T and B lines, Wiskott-Aldrich syndrome, ataxia Telangiectasia, chronic mucocutaneous candidiasis, acrodermatitis enteropathica, Hyper IgE syndrome.
- the complement protein deficit is chosen from the complement component 1 (C1) inhibitor deficiency (hereditary angioedema), C3 deficiency, C4 deficiency, C5, C6 deficiency, C7, C8 and / or C9.
- C1 inhibitor deficiency hereeditary angioedema
- C3 deficiency C4 deficiency
- C5 deficiency C5 deficiency
- C6 deficiency C7, C8 and / or C9.
- the deficit in the activity of the macrophage and of the polynuclear can be chosen from septic granulomatosis, myeloperoxidase deficiency, Chediak Higashi syndrome. actin dysfunction, Shwachman syndrome.
- the immunosuppression can be secondary.
- the secondary immunosuppression can be due to an HIV infection, sarcoidosis, thymoma, thymic hypoplasia, acute leukemia, chronic lymphoid leukemia, malignant lymphoma, multiple myeloma, Waldenstrom's disease, cortisone derivative therapy, immunosuppressive therapy, thymus removal, chemotherapy, radiotherapy, viral infection, bacterial infection, infection caused by fungus and / or yeast, infection caused by a parasite , dietary deficiency, autoimmune disease, chronic renal failure, blood malignancy, toxic blood disease, asplenia, hyposplenia, metabolic disease, cancer affecting the immune system, drug therapy, splenectomy, drug addiction , alcoholism, immunosenescence and combinations thereof, preferably immunosenescence.
- the metabolic disease can be chosen from type 2 diabetes, cirrhosis, non-alcoholic fatty liver disease, obesity, and combinations thereof.
- the treatment can be immunosuppressive therapy, corticosteroid, chemotherapy, radiotherapy, and combinations thereof.
- the immunosuppression can be characterized by at least one of the markers chosen from neutropenia, lymphopenia, a CD4 / CD8 ratio of less than 1, and their combination.
- the invention is particularly useful for treating or preventing immunosenescence.
- the NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts
- NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, as well as the compositions comprising it can be administered to a human aged at least 15 years, preferably at least 20 years, more preferably at least 25 years, more preferably at least 30 years, even more preferably at least 35 years for the prevention of immunosenescence
- the reduction in immunosenescence can be measured by the reduction of a marker chosen from thymic involution, at least one cytokine chosen from IL1, IL2, IL6, IL12, IL15, IL18, IL22; TNF alpha, Interferon gamma, C reactive protein, amounts of senescent T cells resident in spleen, level of circulating IgG immunoglobulin produced by memory B cells, level of circulating IgA immunoglobulin produced by memory B cells, at and their combinations.
- a marker chosen from thymic involution at least one cytokine chosen from IL1, IL2, IL6, IL12, IL15, IL18, IL22; TNF alpha, Interferon gamma, C reactive protein, amounts of senescent T cells resident in spleen, level of circulating IgG immunoglobulin produced by memory B cells, level of circulating IgA immunoglobulin produced by memory B cells, at and their combinations.
- the reduction in immunosenescence can be measured by the increase of a marker chosen from the production of new naive T cells, the ability to respond to new antigens, the accumulation of memory T cells, the number of circulating B cells, levels of circulating immunoglobulin produced by naive cells (IgD and / or IgM), vaccine immunogenicity, increased CD4 / CD8 ratio, IL1-Ralpha level, level of IL4, IL10 level, TGFbeta 1 level, cell sedimentation rate, and combinations thereof.
- a marker chosen from the production of new naive T cells, the ability to respond to new antigens, the accumulation of memory T cells, the number of circulating B cells, levels of circulating immunoglobulin produced by naive cells (IgD and / or IgM), vaccine immunogenicity, increased CD4 / CD8 ratio, IL1-Ralpha level, level of IL4, IL10 level, TGFbeta 1 level, cell sedimentation rate, and combinations thereof.
- a subject of the invention is also a composition
- a composition comprising the nicotinamide mononucleotide, one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives, one of its pharmaceutically acceptable salts, and at least one pharmaceutically acceptable excipient for prevention and / or the treatment of immunosuppression, preferably immunosenescence, as defined above.
- Alkyl by itself or as part of another substituent, denotes a hydrocarbyl radical of formula CnH2n + 1 in which is a number greater than or equal to 1.
- the alkyl groups of This invention comprises from 1 to 12 carbon atoms, preferably from 1 to 8 carbon atoms, more preferably from 1 to 6 carbon atoms, still more preferably from 1 to 2 carbon atoms.
- the alkyl groups can be linear or branched and can be substituted as indicated in the present invention.
- alkyls suitable for the implementation of the invention can be chosen from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl, pentyl and its isomers such as n-pentyl and iso-pentyl, and hexyl and its isomers such as n-hexyl and iso-hexyl, heptyl and its isomers (eg n-heptyl, iso-heptyl), octyl and its isomers (eg n-octyl, iso-octyl), nonyl and its isomers (eg n-nonyl, iso-nonyl), decyl and its isomers (eg n-decyl, iso-decyl), undecyl and its isomers, dodecyl and
- the alkyl groups can be chosen from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl.
- the saturated and branched alkyl groups can be chosen, without limitation, from isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylbutyl, 3-methylbutyle, 2-methylpentyle, 3-methylpentyle, 4-methylpentyle, 2-methylhexyl, 3-methylhexyle, 4-methylhexyle, 5- methylhexyle, 2,3-dimethylbutyle, 2,3-dimethylpentyle, 2,4-dimethylpentyle, 2,3-dimethylhexyle, 2,4-dimethylhexyle, 2,5- dimethylhexyl, 2,2-dimethylpentyl, 2,2-dimethylhexyl, 3,3- dimtheylpentyle, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylpentyl, 3-ethylpentyl, 2-ethyl
- alkyl groups are: methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl.
- Cx-Cy-alkyls refer to alkyl groups which include from x to y carbon atoms.
- alkylene includes methylene, ethylene, methylmethylene, propylene, ethylethylene, and 1,2-dimethylene.
- alkenyl refers to an unsaturated hydrocarbyl group, which may be linear or branched, comprising one or more carbon-carbon double bonds. Suitable alkenyl groups have between 2 and 12 carbon atoms, preferably between 2 and 8 carbon atoms, and even more preferably between 2 and 6 carbon atoms.
- alkenyl groups are ethenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and its isomers, 2-hexenyl and its isomers, 2,4-pentadienyl and groups similar.
- alkynyl denotes a class of monovalent unsaturated hydrocarbyl groups, in which the unsaturation results from the presence of one or more triple bond (s) carbon-carbon.
- Alkynyl groups generally and preferably have the same number of carbon atoms as described above for alkenyl groups.
- Non-limiting examples of alkynyl groups are ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl and its isomers, 2-hexynyl and its isomers, etc.
- Alkoxy denotes an alkyl group as defined above, which is attached to another part by an oxygen atom.
- alkoxy groups include methoxy, isopropoxy, ethoxy, tert-butoxy, and the like.
- the alkoxy groups can be optionally substituted with one or more substituents.
- the alkoxy groups included in the compounds of this invention may be optionally substituted with a solubilizing group.
- Aryl refers to a polyunsaturated aromatic hydrocarbyl group having a single ring (eg phenyl) or more aromatic rings fused together (eg naphthyl) or covalently linked, generally containing 5 to 18 atoms, preferably 5 to 12, more preferably 6 to 10, of which at least one ring is aromatic.
- the aromatic ring can optionally comprise one or two additional rings (cycloalkyl, heterocyclyl or heteroaryl) which are fused therein.
- Aryl is also intended to include partially hydrogenated derivatives of the carbocyclic systems listed herein.
- aryl examples include phenyl, biphenylyl, biphenylenyl, 5- or 6-tetralinyl, naphthalene-1- or -2-yl, 4-, 5-, 6 or 7-indenyl, 1- 2-, 3-, 4- or 5- acenaphthylenyl, 3-, 4- or 5-acenaphthenyl, 1- or 2-pentalenyl, 4- or 5-indanyl, 5-, 6-, 7- or 8-tetrahydronaphthyl , 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl, 1-, 2-, 3-, 4- or 5-pyrenyl.
- heteroaryl When at least one carbon atom in an aryl group is replaced by a heteroatom, the resulting ring is referred to herein as a "heteroaryl" ring.
- Alkylaryl denotes an aryl group substituted by an alkyl group.
- Amino acid denotes an alpha-amino carboxylic acid, that is to say a molecule comprising a carboxylic acid functional group and an amine functional group in the alpha position of the carboxylic acid group, for example a proteinogenic amino acid or a non-proteinogenic amino acid.
- Proteinogenic amino acid denotes an amino acid which is incorporated into proteins during the translation of messenger RNA by ribosomes in living organisms, that is to say Alanine (ALA), Arginine (ARG ), Asparagine (ASN), Aspartate (ASP), Cysteine (CYS), Glutamate (glutamic acid) (GLU), Glutamine (GLN), Glycine (GLY), Histidine (HIS), Isoleucine (ILE), Leucine (LEU) , Lysine (LYS), Methionine (MET), Phenylalanine (PHE), Proline (PRO), Pyrrolysine (PYL), Selenocysteine (SEL), Serine (SER), Threonine (THR), Tryptophan (TRP), Tyrosine (TYR) or Valine (VAL).
- Alanine ALA
- ARG Asparagine
- ASN Asparagine
- ASP Aspartate
- Cysteine Cysteine
- Glutamate Glutamic acid
- Non-proteinogenic amino acid refers to an amino acid which is not naturally encoded or found in the genetic code of a living organism.
- Non-limiting examples of non-proteinogenic amino acids are ornithine, citrulline, argininosuccinate, homoserine, homocysteine, cysteine-sulfinic acid, 2-aminomuconic acid, d-aminolevulinic acid, b -alanine, cystathionine, y-aminobutyrate, DOPA, 5- hydroxytryptophan, D-serine, ibotenic acid, a-aminobutyrate, 2-aminoisobutyrate, D-leucine, D-valine, D-alanine or D-glutamate
- cycloalkyl as used herein is a cyclic alkyl group, i.e. a monovalent, saturated or unsaturated hydrocarbyl group having 1 or 2 ring structures.
- cycloalkyl includes monocyclic or bicyclic hydrocarbyl groups. Cycloalkyl groups can have 3 or more carbon atoms in the ring and generally, according to the present invention, have 3 to 10, more preferably 3 to 8 carbon atoms and even more preferably 3 to 6 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, with cyclopropyl being particularly preferred.
- pharmaceutically acceptable excipient it is meant to a vehicle or an inert support used as solvent or diluent in which the active principle is formulated and / or administered, and which does not produce an undesirable reaction, allergic or the like when administered to an animal, preferably a human.
- the preparations must meet standards of sterility, general safety and purity, such as as required by regulatory offices, such as for example the FDA or GEMA.
- pharmaceutically acceptable excipient includes all pharmaceutically acceptable excipients as well as all pharmaceutically acceptable carriers, diluents and / or adjuvants.
- white blood cells or “leukocytes” is understood to mean the cells of the immune system. This generic term encompasses neutrophils, eosinophils, basophils, T and B lymphocytes as well as monocytes.
- Halogen or "halo" means fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro and chloro.
- Haloalkyl denotes an alkyl radical having the meaning as defined above, in which one or more hydrogen atoms are replaced by a halogen as defined above.
- haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like.
- Cx-Cy-haloalkyl and Cx-Cy-alkyl denote alkyl groups which have from x to y carbon atoms.
- Preferred haloalkyl groups are difluoromethyl and trifluoromethyl.
- Heteroalkyl denotes an alkyl group as defined above, in which one or more carbon atoms are replaced by a heteroatom chosen from oxygen, nitrogen and sulfur atoms.
- heteroatoms are linked along the alkyl chain only to carbon atoms, i.e. each heteroatom is separated from all other heteroatom by at least one carbon atom.
- the nitrogen and sulfur heteroatoms can optionally be oxidized and the nitrogen heteroatoms can optionally be quaternized.
- a heteroalkyl is bonded to another group or molecule only through a carbon atom, i.e. the linking atom is not selected from heteroatoms included in the heteroalkyl group.
- heteroaryl denotes, without limitation, aromatic rings of 5 to 12 carbon atoms or ring systems containing 1 or 2 rings which are fused or covalently linked, generally containing 5 or 6 atoms; at least one of which is aromatic, in which one or more carbon atoms in one or more of these rings are replaced by oxygen, nitrogen and / or sulfur atoms, the nitrogen and sulfur heteroatoms possibly possibly be oxidized and the nitrogen heteroatoms possibly being quaternized.
- These rings can be fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl ring.
- heteroaryls no limitative of such heteroaryls, mention may be made of furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazinyl, pyridiazinyl, oxatriazinyl, thiatriazolyl, pyridiazinyl, thiatriazolyl, pyridiazinyl, thiatriazolyl, pyridiazine triazinyl, imidazo [2, 1 -b] [1, 3] thiazolyl, thieno [3, 2-b] furanyl, thieno [3, 2-b] thiophenyl, thieno [2,3-d] [1,3] thi
- heterocycloalkyl When at least one carbon atom in a cycloalkyl group is replaced by a heteroatom, the resulting ring is referred to herein as “heterocycloalkyl” or “heterocyclyl”.
- heterocyclyl refers to non-aromatic, fully saturated or partially cyclic groups.
- unsaturated eg, 3- to 7-membered monocyclic, 7 to 11-membered bicyclic, or containing a total of 3 to 10 ring atoms
- that have at least one heteroatom in at least one ring containing one carbon atom denotes unsaturated (eg, 3- to 7-membered monocyclic, 7 to 11-membered bicyclic, or containing a total of 3 to 10 ring atoms) that have at least one heteroatom in at least one ring containing one carbon atom.
- Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and / or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the Nitrogen heteroatoms can optionally be quaternized. Any of the carbon atoms of the heterocyclic group can be substituted with an oxo (eg piperidone, pyrrolidinone).
- the heterocyclic group can be attached to any heteroatom or carbon atom of the ring or ring system, when valence permits.
- the rings of multi-ring heterocycles can be fused, bridged and / or linked by one or more spiro atoms.
- heterocyclic groups include oxetanyl, piperidinyl, azetidinyl, 2-imidazolinyl, pyrazolidinyl, imidazolidinyl, isoxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, 3H-isothiazolidinyl, piperidinyl, 3H-isothiazolidinyl, piperidinyl, homzolinopinipolinopinipolinopipolinopipolinopinyl, 2-pipolinopinipolinopipolinopinyl, 2-pipolinopinipolinopinyl, inderazolinopinyl, 3H-iso-iso-indolinopidazolidinyl, oxazolidine , 2-pyrazolinyl, 3-pyrazolinyl,
- leukopenia designates a blood disorder characterized by a number of white blood cells less than 4000 those / ⁇ l of blood.
- lymphopenia denotes a blood disorder characterized by a lower than normal number of lymphocytes during a blood count, ie less than 1500 per mm 3 .
- neutrophils are hematological disorder characterized by a low level of granulocytes, or polymorphonuclear, neutrophils in the blood.
- Normal neutropenia is set at less than 2000 neutrophils / mi of blood.
- Mild neutropenia corresponds to a level of 1000 to 1500 neutrophils / ml of blood.
- Moderate neutropenia corresponds to a level of 500 to 1000 neutrophils / ml of blood.
- Severe neutropenia corresponds to a level of less than 500 neutrophils / ml of blood.
- Agranulocytosis corresponds to a neutrophil count of less than 100 / mm3 of blood.
- the expression “elderly person” designates a human chosen from a human aged at least 60 years, a human at least 65 years old, a human at least 70 years old, a human at least 75 years old. years old, a human of at least 80 years old, a human of at least 85 years old, a human at least 90 years old, a human at least 95 years old.
- precursors as used here also denotes the pharmacologically acceptable derivatives of the compounds of formula (I) or (Ia) such as esters of which the product of in vivo biotransformation is the active drug.
- the precursors are characterized by increased bioavailability and are readily metabolized to active compounds in vivo.
- the precursors suitable for the purposes of the invention include in particular the carboxylic esters, in particular the alkyl esters, the aryl esters, the acyloxyalkyl esters and the carboxylic esters of dioxolene; ascorbic acid esters.
- “Pharmaceutically acceptable” means approved or likely to be approved by a regulatory body or listed in a pharmacopoeia recognized for use in animals, and more preferably in humans. It may be a substance which is not biologically or otherwise undesirable, i.e. the substance can be administered to an individual without causing adverse biological effects or harmful interactions with one of the components of the composition in which it is contained.
- a “pharmaceutically acceptable” salt or excipient denotes any salt or any excipient authorized by the European Pharmacopoeia (denoted “Ph. Eur.”) And the American Pharmacopoeia (denoted by “United States Pharmacopeia (USP)” in English).
- the term "active principle” denotes a molecule or a substance whose administration to a subject slows down or stops the progression, worsening or deterioration of one or more symptoms of a disease or a condition. ; relieves symptoms of a disease or condition; cures a disease or condition.
- the therapeutic ingredient is a small molecule, natural or synthetic.
- the therapeutic ingredient is a biological molecule such as, for example, an oligonucleotide, an siRNA, a miRNA, a DNA fragment, an aptamer, an antibody and the like.
- “Pharmaceutically acceptable salts” include the acid and base addition salts of such salts. Suitable acid addition salts are formed from acids which form non-toxic salts.
- Suitable basic salts are formed from bases which form non-toxic salts. Mention may be made, as examples, of the salts of aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, 2- (diethylamino) ethanol, ethanolamine, morpholine, 4- (2-hydroxyethyl) morpholine and zinc. Acid and base hemi-salts can also be formed, for example, hemi-sulphates and chemical calcium salts.
- Preferred pharmaceutically acceptable salts are hydrochloride / chloride, bromide / hydrobromide, bisulfate / sulfate, nitrate, citrate and acetate.
- Pharmaceutically acceptable salts can be prepared by one or more of these methods: by reacting the compound with the desired acid; ii. reacting the compound with the desired base; iii. by removing a protective group labile in acid or basic medium from a suitable precursor of the compound or by opening the ring of a suitable cyclic precursor, for example a lactone or a lactam, using the desired acid; or iv. converting one salt of the compound into another by reaction with a suitable acid or by means of a suitable ion exchange column.
- the salt can precipitate from solution and be collected by filtration or can be recovered by evaporating the solvent.
- the degree of ionization of the salt can vary from fully ionized to almost non-ionized.
- solvent is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- substituted means that a hydrogen radical on a compound or a group is replaced by any desired group which is substantially stable under the conditions of the reaction in an unprotected form or when it is. protected by a protective group.
- substituents include, but are not limited to, halogen (chloro, iodo, bromo or fluoro); an alkyl; alkenyl; alkynyl, as described above; a hydroxy; an alkoxy; a nitro; a thiol; a thioether; an imine; a cyano; an amido; a phosphonato; a phosphine; a carboxyl; a thiocarbonyl; a sulfonyl; a sulfonamide; a ketone; an aldehyde; an ester; an oxygen (-O); haloalkyl (eg, trifluoromethyl); cycloalkyl, which may be condensed or non-condensed monocyclic or polycyclic (eg, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or heterocycloalkyl
- aryl, heteroaryl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiazinyl monocyclic or polycyclic fused or unfused (e.g. aryl, heteroaryl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiazinyl), monocyclic or polycyclic fused or unfused (e.g.
- pyrrolidinyl piperidinyl, piperazinyl, morpholinyl or thiazinyl
- phenyl, naphthyl pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyrazinyl, isonazolinyl, pyrazolyl, pyrrazinyl, quinazolinyl, pyrazolyl, pyridyl, isonazolinyl, pyrazolyl, pyrrazinyl, quinazolinyl, pyrazolyl, pyrazinyl, isonazolinyl, pyrazolyl, pyrrazinyl, quinazolinyl, pyrazolyl, pyrazinyl, isonazolinyl, pyr
- substituted denotes a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, a heteroarylalkyl, a haloalkyl, - C (0) NRnRi2, -NR I3 C (0) R I4 , a halo, -OR13, cyano, nitro, a haloalkoxy, -C (0) R13, -NR11R12, -SR13, - C (0) 0Ri3, -0C (0) Ri3, -NRi 3 C (0) NRnRi 2 , -0C (0) NRUR I2 , -NR I3 C (0) 0R I4 , -S (0) rR13, -NR
- administration means to provide the active principle, alone or in the framework of a pharmaceutically acceptable composition, to the patient in whom / to whom the The condition, symptom or disease must be treated or prevented.
- Treatment as used in the present invention are intended to include the alleviation, alleviation or ablation of a condition or disease and / or its associated symptoms.
- Prevent refers to a method of delaying or preventing the onset of a condition or disease. and / or its related symptoms, to prevent a patient from acquiring a condition or disease, or to reduce the risk of a patient for contracting a condition or disease.
- bonds of an asymmetric carbon can be represented here using a solid triangle ( “" “ * ), a dotted triangle ( “" ”) or a zigzag line (' wv ').
- the present invention relates to nicotinamide mononucleotide (NMN), one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts for its use in the prevention and / or treatment of immunosuppression, preferably immunosenescence .
- NNN nicotinamide mononucleotide
- a subject of the present invention is also a composition comprising NMN, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient for its use in the prevention and / or treatment of immunosuppression, preferably immunosenescence.
- Nicotinamide adenine dinucleotide is a coenzyme present in all living cells. NAD exists in the cell either in its oxidized form NAD + or in its reduced form NADH. The role of NAD is that of an electron transporter involved in the redox reactions of the metabolism. NAD is also involved in many cellular processes such as ADP ribosylation as part of post-translational protein modifications.
- NAD can be synthesized de novo by the cell from amino acids such as tryptophan or aspartate. However, this synthesis is marginal because the main route of NAD synthesis is the rescue route by which the cell, and mainly the cell nucleus, recycles compounds to reform NAD from precursors.
- the precursors of NAD include niacin, nicotinamide riboside, nicotinamide mononucleotide, and nicotinamide.
- NMN is one of the compounds allowing the synthesis of NAD by the rescue route and has the formula:
- the NMN is in the form of a zwitterion.
- zwitterion is understood to mean a molecular chemical species possessing electric charges of the opposite sign and located, in general, on non-adjacent atoms of the molecule.
- NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, as well as the compositions comprising them can be used to treat or prevent immunosuppression, preferably immunosenescence.
- NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, can be administered to a mammal, preferably a human.
- the immunosuppression can be a primary immunosuppression or a secondary immunosuppression.
- the primary immunosuppression is of hereditary origin and can be chosen from humoral predominance, cellular predominance, a combined deficiency, a deficiency in complement proteins, or a deficiency in the activity of the macrophage and the polynucelar.
- the predominantly humoral primary immunosuppression can be chosen from agammaglobulinemia linked to sex or Bruton's disease, common hypogammaglobulinemia of variable expression or a selective deficit in immunoglobulins such as a deficiency in IgA, IgD, IgG and / or IgM.
- the predominantly cellular primary immunosuppression can be chosen from 22qll microdeletion or Di George's syndrome, Hong and Good's syndrome, Nezelof's syndrome, purine nucleoside phosphorylase deficiency, isolated T lymphocyte deficiency.
- the combined deficit can be chosen from the severe combined immunodeficiency by adenosine deaminase deficiency. denuded lymphocyte syndrome, congenital amegakaryocytosis with developmental abnormality of T and B lines, Wiskott-Aldrich syndrome, ataxia Telangiectasia, chronic mucocutaneous candidiasis, acrodermatitis enteropathica, Hyper IgE syndrome.
- the deficit of macrophage and polynuclear activity can be chosen among septic granulomatosis, myeloperoxidase deficiency, Chediak Higashi syndrome. actin dysfunction, Shwachman syndrome.
- the complement protein deficiency can be chosen from the complement component 1 (C1) inhibitor deficiency (hereditary angioedema), C3 deficiency, C4 deficiency, C5, C6, C7 deficiency. , C8 and / or C9.
- C1 inhibitor deficiency hereditary angioedema
- C3 deficiency C3 deficiency
- C4 deficiency C5, C6, C7 deficiency.
- the immunosuppression can be secondary or acquired.
- secondary immunosuppression may be due to HIV infection, sarcoidosis, thymoma, thymic hypoplasia, acute leukemia, chronic lymphoid leukemia, malignant lymphoma, multiple myeloma, Waldenstrom's disease, treatment by a cortisone derivative, immunosuppressive therapy, thymus removal, chemotherapy, radiotherapy, viral infection, bacterial infection, infection caused by fungus and / or yeast, infection caused by a parasite, nutritional deficiency, autoimmune disease, chronic renal failure, hematologic malignancy, toxic hematologic disease, asplenia, hyposplenia, metabolic disease, cancer affecting the immune system, drug therapy, splenectomy, drug addiction, alcoholism, immunosenescence and combinations thereof, preferably immunosenescence.
- the metabolic disease can be selected from type 2 diabetes, cirrhosis, non-alcoholic fatty liver disease, obesity, and combinations thereof.
- the treatment can be immunosuppressive treatment, a corticosteroid, chemotherapy, radiotherapy and their combinations.
- the radiotherapy can be chosen from X-ray or gamma irradiation.
- the chemotherapy can be chosen from an antimetabolite, an alkylating agent, a topoisomerase inhibitor, an anthracycline, and combinations thereof.
- the alkylating agent can be chosen from dacarbazine, temozolomide, streptozocin, cyclophosphamide, ifofosfamide, melphalan, procarbazine, busulfan, triphosphoramide, rhexamethylmelamine, chlormethine, platinum salts such as cisplatin, carboplatin, oxaliplatin and their combinations.
- the antimetabolite can be selected from azathioprine, methotrexate, mycophenolic acid, mycophenolate mofetil, fludarabine, and combinations thereof.
- Anthracycline can be selected from doxorubicin, pegylated doxorubicin, daunorubicin, epirubucin, mitoxantrone, pirarubicin, idarubicin, acinomycin D, amsacrine, and combinations thereof.
- the topoisomerase inhibitor can be chosen from topoisomerase 1 inhibitors and topoisomerase 2 inhibitors and their combination. We can by way of example of topoisomerase 1 inhibitors, mention irinotecan and topotecan. As examples of topoisomerase 2 inhibitors, mention may be made of anthracyclines and etoposide.
- the at least one therapeutic agent is an immunosuppressive treatment.
- the immunosuppressive treatment can be chosen from an anti-metabolite, a TNF alpha inhibitor, an interleukin-1 (IL1) inhibitor, a cortisone derivative, a calcineurin inhibitor, rapamycin, a anti-CD25 antibodies, lymphoablative therapy and combinations thereof.
- IL1 interleukin-1
- cortisone derivative a cortisone derivative
- calcineurin inhibitor a calcineurin inhibitor
- rapamycin a anti-CD25 antibodies
- lymphoablative therapy lymphoablative therapy and combinations thereof.
- the antimetabolite can be chosen from azathioprine, methotrexate, mycophenolic acid, mycophenolate mofetil, fludarabine, and their combinations.
- the cortisone derivative is chosen from betamethasone, ciprofloxacin, cortivazol, dexamethasone, fludrocortisone, methylprednisolone, prednisolone, triamcinolone and their combinations.
- the calcineurin inhibitor can be chosen from cyclosporine, tacrolimus and their combinations.
- the lymphoablative treatment can be chosen from chemotherapy, radiotherapy, an alkylating agent, an intercalator, an anthracycline, anti-thymocyte globulins, a CD52 monoclonal antibody, an OKT3 monoclonal antibody and their combinations.
- the immunosuppression can be characterized by at least one of the markers chosen from neutropenia, lymphopenia, a CD4 / CD8 ratio of less than 1, and their combination.
- the CD4 + / CD8 + ratio is the ratio of helper T cells (with the CD4 surface marker) and cytotoxic T cells (with the CD8 surface marker).
- the CD4 + / CD8 + ratio in the peripheral blood of healthy adults and mice is approximately 2: 1, and an altered ratio may indicate diseases related to immunodeficiency or autoimmunity.
- An inverted CD4 + / CD8 + ratio indicates an impaired immune system.
- the invention is particularly useful for treating or preventing immunosenescence.
- the reduction in immunosenescence can be measured by the reduction of a marker chosen from thymic involution, at least one cytokine chosen from IL1, IL2, IL6, IL12, IL15, IL18, IL22; TNF alpha, Interferon gamma, the increase of at least one cytokine selected from IL1-Ralpha, IL4, IL10, TGFbeta 1.1a C reactive protein, the amounts of senescent T cells resident in the spleen, the level of immunoglobulin IgG circulating produced by memory cells B, the level of circulating immunoglobulin IgA produced by memory cells B, to and their combinations.
- Thymic involution corresponds to a reduction in the volume of the thymus. The reduction in immunosenescence can be observed as the size of the thymus increases.
- the reduction in immunosenescence can also be measured by the increase of a marker chosen from the production of new naive T cells, the capacity to respond to new antigens, the accumulation of memory T cells, the number circulating B cells, the level of circulating immunoglobulin IgD produced by naive cells, the level of circulating immunoglobulin IgM produced by naive cells, vaccine immunogenicity, CD4 / CD8 ratio, ILIRa level, blood level IL4 level, IL10 level, TGFbeta-1 level, sedimentation rate, and combinations thereof.
- a marker chosen from the production of new naive T cells, the capacity to respond to new antigens, the accumulation of memory T cells, the number circulating B cells, the level of circulating immunoglobulin IgD produced by naive cells, the level of circulating immunoglobulin IgM produced by naive cells, vaccine immunogenicity, CD4 / CD8 ratio, ILIRa level, blood level IL4 level, IL10 level
- the inventors have demonstrated that the use of the compounds according to the invention, preferably the compounds 1A and 1B, make it possible in particular to increase the size of the thymus, to increase the number of CD8 + thymocytes, of increase the number of B lymphocytes in the bone marrow, increase the number of CD38 + B lymphocytes in the bone marrow, increase the number of CD45 + B lymphocytes in the bone marrow, increase the number of B lymphocyte precursors in bone marrow, increase the number of CD45 + T cells in the spleen, increase the number of activated B cells in the spleen, increase the number of memory B cells in the spleen, increase the number of cells Germline B cells in the spleen, increase the number of CD4 + T cells in the spleen, increase the number of memory CD4 + T cells in the spleen, increase the number of CD4 + effector T cells, increase the number of CD4 + T cells in the spleen, to increase the number memory
- NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, can be administered to a human aged at least 40 years old, preferably at least 45 years old, preferably at least 50 years old, preferably at least 55 years old, preferably at least 60 years old, preferably at least 65 years old, more preferably at least 70 years old, even more preferably at least 75 years old, even more preferably at least 80 years old to treat immunosenescence.
- NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, as well as compositions comprising it can be administered to a human at least 15 years old, preferably at least 20 years old, more preferably at least 25 years old, more preferably at least 30 years old, of even more preferably at least 35 years for the prevention of immunosenescence.
- Nicotinamide mononucleotide one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, as well as the compositions comprising them can be administered orally, ocular, sublingually, parenterally, transcutaneous, vaginal, epidural, intravesical, rectal or inhalation.
- the nicotinamide mononucleotide (NMN), one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts can be administered orally or parenterally, preferably orally.
- the parenteral route can be chosen from the intraarterial route, the intravenous route, the intramuscular route, the subcutaneous route, the intraperitoneal route, more preferably the intravenous route.
- the NMN and the composition according to the invention are administered orally.
- the composition according to the invention can be in the form of a tablet, a capsule, a sachet, a granule, a soft capsule, a lyophilizate, a lozenge. , a suspension, a gel, a syrup, a solution, a water / oil emulsion, an oil / water emulsion, an oil, a cream, a milk from a spray, ointment, ampoule, suppository, eye drops, vaginal ovum, vaginal capsule, liquid for inhalation, dry powder inhaler, pressurized valve inhaler doser.
- the composition according to the invention is in the form of a gastro-resistant capsule or of a sublingual tablet.
- the term “gastro-resistant” is understood to mean a galenic form which does not dissolve in the stomach. Such dosage forms are delayed release, that is to say they have a coating or a coating composition resistant to the acidic pH of the stomach (pH ⁇ 2) to dissolve in the intestine.
- the gastro-resistant character is determined by following the test established by the European Pharmacopoeia. Briefly, the gastro-resistance of a capsule is measured in acid 0.1 M hydrochloric acid at 37 ° C as a disintegrating medium in a disintegrating apparatus. This medium mimics the physicochemical conditions of the stomach. The capsules are incubated in this medium for 1 hour. The capsule must not show any signs of disintegration or cracks which could lead to loss of content.
- the capsule is then incubated for 1 hour in a phosphate buffer solution of pH 6.8 at 37 ° C., this solution mimicking the conditions of the intestinal environment in accordance with the recommendations of the European Pharmacopoeia.
- the capsule should be completely disintegrated within an hour.
- sublingual tablet is understood to mean a galenic form placed under the tongue so that the active principle is absorbed by the sublingual mucosa, and in particular by the vein and artery ranins.
- the galenic form of the composition according to the invention can also be immediate release: such a galenic form allows rapid absorption of the NAD precursor and thus a reduced time of action.
- Immediate-release dosage forms are in particular dispersible, orodispersible, effervescent tablets and oral lyophilisates.
- the galenic form of the composition according to the invention can also be a delayed release. Dissolution and absorption of the NAD precursor take place in the intestine, which limits gastric irritation or the degradation of fragile active ingredients at acidic pH. They are mainly gastroresistant forms, that is to say that the tablets or granules are covered with a polymeric film, insoluble in acidic medium but permeable to water in alkaline medium or of the lipid type degraded by lipases. intestinal.
- the galenic form of the composition according to the invention can also be sustained and sequential release.
- the forms with sequential release (release at specific time intervals) and prolonged (continuous release of the active principle until exhaustion) promote the spreading of the release of the active principle over time in order to maintain an effective plasma concentration for longer in the cell. organism of the patient.
- a suitable dosage level may be about 0.01 to 250 mg / kg per day, about 0.05 to 100 mg / kg per day, or about 0.1 to 50 mg / kg. per day. Within this range, the dose can be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg / kg per day.
- the compositions are preferably provided in tablet form containing 1.0 to 1000 milligrams of the active ingredient, especially 1.0, 5.0, 10.0, 15.0, 20.0, 25 , 0, 50.0, 75. 0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0 and 1000.0 milligrams of the active ingredient for symptomatic patient dose adjustment treat.
- the dosage can be between 100mg / day and 5000mg / day, preferably between 500mg / day and 1000mg / day.
- the Compounds can be administered on a schedule of 1 to 4 times per day, preferably one, two or three times per day. Three times a day is fine.
- the duration of treatment depends on the patent and is determined by the doctor. It can range from one day to a year or even longer, preferably from one week to three months, more preferably from two weeks to six weeks. It will be understood, however, that the specific dose level and frequency of dosing as well as the duration for a given patient may vary and will depend on various factors, including the activity of the specific compound employed, the metabolic stability and the duration of action of. this compound, age, body weight, general health, sex, diet, method and time of administration, rate of excretion, combination of drugs, and the host subjected to treatment.
- NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, can be administered at a daily dose of 10 mg / kg, with a maximum of 1 g / day.
- the NMN can be administered at a daily dose of 10 mg / kg, with a maximum of 1 g /. day for a period of 10 to 60 days, preferably for a period of 14 to 42 days, more preferably for a period of about 30 days preceding the administration of at least one additional therapeutic agent, preferably a vaccine or a vaccine booster.
- NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, can be administered on day 1, on day 2, on day 3, on day 4, on day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 13, day 14, day 15, day 16, day 17, day 18, day 19, day 20, day 21, day 22, day 23, day 24, day 25, day 26, day 27, day 28, day 29, day 30, on day 31.
- NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, can be used in an amount of between 5 mg / day and 1000 mg / day.
- the NMN and the composition according to the invention are used in combination with at least one additional therapeutic agent.
- the composition according to the invention comprises NMN or a pharmaceutically acceptable salt, a pharmaceutically acceptable excipient and at least one additional therapeutic agent.
- an "excipient" denotes any substance other than NMN in the composition and having no therapeutic effect. The excipient does not chemically interact with NMN or any additional therapeutic agent.
- NMN one of its pharmaceutically acceptable precursors, one of its pharmaceutically acceptable derivatives or one of its pharmaceutically acceptable salts, as well as the compositions comprising it can be administered in combination with at least one other therapeutic agent.
- the at least one other therapeutic agent is a vaccine which can be chosen from live attenuated vaccines and inactivated vaccines.
- said vaccine is chosen from a vaccine against a virus, a bacterium, a parasite or a yeast and / or a fungus, or their combinations.
- said vaccine is a vaccine against a virus chosen from Influenzavirus, Coronavirus, Respirovirus, Pneumovirus, Metapneumovirus, Adenovirus, Enterovirus, Rhinovirus, Hepatovirus, Erbovirus, Aphtovirus, Norovirus, Alphavirus, Rubivirus, Flavivirus, Hepacivirus, Ebola, Morbillivirus, Rubulavirus, Henipavirus, Arenavirus, Orthobunyavirus, Phlebovirus, Rotavirus, Simplexvirus, Varicellovirus, Papillomavirus, Cytomegalovirus or their combinations.
- a virus chosen from Influenzavirus, Coronavirus, Respirovirus, Pneumovirus, Metapneumovirus, Adenovirus, Enterovirus, Rhinovirus, Hepatovirus, Erbovirus, Aphtovirus, Norovirus, Alphavirus, Rubivirus, Flavivirus, Hepacivirus, Ebola, Morbillivirus, Rubulavirus, Henip
- said vaccine is a vaccine against a bacterium selected from Pneumococcus, Streptococcus, Corynebacterium, Clostridium, Mycobacterium, Bordetella, Neisseiri and their combinations.
- said vaccine is a vaccine against a parasite selected from Schistosoma, Leishmania, Babesia and their combinations.
- said vaccine is a vaccine against a yeast and / or a fungus selected from Trichophyton, Toxoplasma, Eimeria, Candida and their combinations.
- said vaccine is a vaccine against a bacterium selected from Pneumococcus, Streptococcus, Corynebacterium, Clostridium, Mycobacterium, Bordetella, Neisseiri and their combinations.
- the Mycobacterium is Mycobacterium tuberculosis.
- said Nesseiria is Neisseria meningitis.
- said vaccine is a vaccine against a parasite selected from Schistosoma, Leishmania, Babesia and their combinations.
- said vaccine is a vaccine against a yeast and / or a fungus selected from Trichophyton, Toxoplasma, Eimeria, Candida and their combinations.
- the at least one therapeutic agent is radiotherapy, chemotherapy or combinations thereof.
- the radiotherapy can be chosen from X-ray or gamma irradiation.
- the chemotherapy can be chosen from an antimetabolite, an alkylating agent, a topoisomerase inhibitor, an anthracycline, and their combinations as defined above.
- the alkylating agent can be chosen from dacarbazine, temozolomide, streptozocin, cyclophosphamide, ifofosfamide, melphalan, procarbazine, busulfan, triphosphoramide, rhexamethylmelamine, chlormethine, platinum salts such as cisplatin, carboplatin, oxaliplatin and their combinations.
- the antimetabolite can be selected from azathioprine, methotrexate, mycophenolic acid, mycophenolate mofetil, fludarabine, and combinations thereof.
- Anthracycline can be selected from doxorubicin, pegylated doxorubicin, daunorubicin, epirubucin, mitoxantrone, pirarubicin, idarubicin, acinomycin D, amsacrine, and combinations thereof.
- the topoisomerase inhibitor can be chosen from topoisomerase 1 inhibitors and topoisomerase 2 inhibitors and their combination.
- topoisomerase 1 inhibitors mention may be made of irinotecan and topotecan.
- topoisomerase 2 inhibitors mention may be made of anthracyclines and etoposide.
- the at least one therapeutic agent is an immunosuppressive treatment.
- the immunosuppressive treatment can be chosen from an anti-metabolite, a TNF alpha inhibitor, an interleukin-1 (IL1) inhibitor, a cortisone derivative, a calcineurin inhibitor, rapamycin, a anti-CD25 antibodies, lymphoablative therapy and combinations thereof.
- IL1 interleukin-1
- cortisone derivative a cortisone derivative
- calcineurin inhibitor a calcineurin inhibitor
- rapamycin a anti-CD25 antibodies
- lymphoablative therapy lymphoablative therapy and combinations thereof.
- the antimetabolite can be chosen from azathioprine, methotrexate, mycophenolic acid, mycophenolate mofetil, fludarabine, and their combinations.
- the cortisone derivative is chosen from betamethasone, ciprofloxacin, cortivazol, dexamethasone, fludrocortisone, methylprednisolone, prednisolone, triamcinolone and their combinations.
- the calcineurin inhibitor can be chosen from cyclosporine, tacrolimus and their combinations.
- the lymphoablative treatment can be chosen from chemotherapy, radiotherapy, an alkylating agent, an intercalator, an anthracycline, anti-thymocyte globulins, a CD52 monoclonal antibody, an OKT3 monoclonal antibody and their combinations.
- the excipient can be chosen from a bulking agent, a lubricant, a flavoring, a colorant, an emulsifier, a compressing agent, a diluent, a preservative, a gelling agent, a plasticizer, a surfactant or their combinations. Those skilled in the art know which excipient to choose depending on the dosage form that they have chosen.
- composition according to the invention can be a pharmaceutical composition.
- the excipient is a pharmaceutically acceptable excipient as defined above.
- composition according to the invention can also be a food supplement.
- the NMN derivative can be chosen from alpha nicotinamide mononucleotide ( ⁇ -NMN), dihydronicotinamide mononucleotide (denoted NMN-FI), the compound of formula (I):
- R 1 is selected from H, azido, cyano, C 1 -C 6 alkyl, thio-C 1 -C 6 alkyl, C 1 -C 8 heteroalkyl and OR; wherein R is selected from F1 and C1-C8 alkyl;
- R2, R3, R4 and R 5 are independently selected from F1, halogen, azido, cyano, hydroxyl, C1-C12 alkyl, thio-C1-C12 alkyl, C1-C12 heteroalkyl, haloalkyl in C1-C12 and OR; wherein R is selected from F1, C1-C12 alkyl, C (0) (Ci-Ci 2 ) alkyl, C (0) NFI (Ci-Ci 2 ) alkyl, C (0) 0 (Ci-Ci2) alkyl , C (0) aryl, C (0) (Ci-Ci 2 ) alkyl aryl, C (0) NFI (Ci-Ci 2 ) alkyl aryl, C (0) 0 (Ci-Ci 2 ) alkyl aryl and C ( 0) CFIR AA NFI 2 ; wherein R AA is a side chain selected from a proteinogenic amino acid; R 6 is selected from H
- R 7 is chosen from in which n is an integer equal to 1 or 3; in which
- Rg and Rio are independently selected from OH, ORn, NHR 13 , NR 13 R 14 , C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl , a C 3 -C 10 cycloalkyl, a C 5 -C 12 aryl, (Ci-Cg) alkyl aryl, (Ci-Cg) aryl alkyl, (Ci-Cg) heteroalkyl, (Ci-Cg) heterocycloalkyl, a heteroaryl and NHCHR A R A ' C (0) RI 2 ; in which :
- Ru is chosen from a Ci-Cioalkyl, C 3 -C 10 cycloalkyl, C 5 -Cig aryl, C 1 -C 10 alkylaryl, C 5 - C 12 substituted aryl, C 1 -C 10 heteroalkyl, C 3 -C 10 group heterocycloalkyl, C 1 -C 10 haloalkyl, a heteroaryl, - (CH 2 ) favourC (0) (Ci-Ci 5 ) alkyl, - (CH 2 ) n OC (0) (Ci-Ci 5 ) alkyl, - ( CH 2 ) n OC (0) 0 (Ci-Ci 5 ) alkyl, - (CH 2 ) favourSC (0) (C 1 - Ci 5 ) alkyl, - (CH 2 ) n C (0) 0 (Ci- Ci 5 ) alkyl and - (CH 2 ) n C (0) 0 (Ci-Ci
- R 12 is selected from H, C 1 -C 10 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 1 -C 10 haloalkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, C 5 -Cig aryl, C 1 -C 4 alkylaryl and C 5 -C 12 heteroaryl; wherein said aryl or heteroaryl groups are optionally substituted from one or two groups selected from halogen, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy and cyano; and
- R is selected from H, (Cs-Ce) aryl and (Cs-Ce) heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with halogen, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy and cyano;
- Rg and Rio together with the phosphorus atoms to which they are attached form a 6-membered ring in which -R9-R10- represents -O-CH2-CH2-CHR-O-; wherein R is selected from H, (Cs-Ce) aryl and (Cs-Ce) heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with halogen, trifluoromethyl, (Ci-Ce) alkyl, ( Ci-Ce) alkoxy and cyano;
- Rg is selected from H, OR, NHR 13 , NR 13 R 14 , NH-NHR 13 , SH, CN, N 3 and halogen; wherein R 13 and R14 are independently selected from H, (C1-Cg) alkyl and (C1-Cg) alkyl aryl;
- Y is selected from CH, CH 2 , C (CH 3 and CCH 3 ;
- a ' w ' represents the alpha or beta anomer depending on the position of Ri or one of its stereoisomers, one of its salts, one of its hydrates, one of its solvates or one of its crystals or the compound of formula (Ia):
- R'i and R '13 are independently selected from H, azido, cyano, C1-C8 alkyl, thio-C1-C8 alkyl, C1-C8 heteroalkyl, and OR, wherein R is selected from H and a C1-C8 alkyl,
- R '2, R' 3, R '4, R' 5, R '9, R' 10, R '11, R' 12 are independently selected from H, halogen, azido, cyano, hydroxyl, a C 1 -C 12 thioalkyl a C 1 -C 12 alkyl, hetero-alkyl -C C12 haloalkyl -C Ci2et OR, wherein R may be selected from H, C1-C12, C (0) (C1-C12) alkyl, C (0) NH (Ci-Ci 2) alkyl, a C (0) 0 (Ci-Ci 2 ) alkyl, a C (O) aryl, a C (0) (C1-C12) aryl, a C (0) NH (Ci-Ci 2 ) alkyl aryl, a C (0) 0 (Ci-Ci 2 ) alkyl aryl or a group C (0) CHR AA NH2 in
- R ' 6 and R'g are independently selected from H, azido, cyano, C1-C8 alkyl and OR, wherein R is selected from H and C1-C8 alkyl;
- R ' 7 and R' 14 are independently selected from H, OR, NHR, NRR ', NH-NHR, SH, CN, N3 and halogen, wherein R and R' are independently selected from H and (Ci-Cg ) alkyl aryl;
- U ⁇ and Y'2 are independently selected from CH, CH2, C (CH B ) 2 OR CCH 3 ;
- M ' is chosen from H or a suitable counterion
- the pharmaceutically acceptable derivative is the compound of formula (I).
- X represents an oxygen
- R 1 and R 6 each represent, independently of one another, a hydrogen.
- R 2 , R 3 , R 4 and R 5 each represent, independently of one another, a hydrogen or an OH.
- Y represents a CH.
- Y represents a CH2.
- R 7 represents hydrogen
- R 7 represents P (0) (OH) 2 .
- the compound of the invention is chosen from the compounds of formula I-A to I-J:
- the pharmaceutically acceptable derivative is alpha-NMN of formula:
- the pharmaceutically acceptable derivative is the compound of formula (Ia).
- C ⁇ and X'2 each independently represent oxygen.
- R'7 and R'14 each independently represent an NH2.
- R'I and / or R'13 each independently represent a hydrogen.
- R'6 and / or R'8 each independently represent a hydrogen.
- R'2, R'3, R'4 , R'5, R'9, R'10, R'11 and R'12 each independently represent hydrogen.
- R'2, R'3, R'4 , R'5, R'9, R'10, R'11 and R'12 each independently represent an OH.
- Y'1 and Y'2 each independently represent a CH.
- U ⁇ and Y'2 each independently represent a CH2.
- the compound according to the invention is chosen from the compounds of formula la-A to la-l:
- the pharmaceutically acceptable derivative is NMN-H:
- the pharmaceutically acceptable precursor is nicotinamide riboside (denoted NR):
- the precursor is nicotinamide riboside (NR).
- the derivative of NMN is dihydronicotinamide mononucleotide (NMN-H) and / or alpha-NMN.
- the derivatives of formula (I) as well as the alpha-NMN can be prepared according to the method described below.
- the invention relates to a method for preparing the compounds of formula (I) as described above.
- the method involves in a first step the mono-phosphorylation of a compound of formula (A), in the presence of phosphoryl chloride and of a trialkyl phosphate, to lead to the phosphorodichloridate of formula (B),
- the compound of formula (A) is synthesized using various methods known to those skilled in the art.
- the compound of formula (A) is synthesized by reaction of the pentose of formula (D) with a nitrogen derivative of formula (E), in which R, R2, R3, R4, Rs, R 6 , R7, Y are as described above for the compounds of formula I, leading to the compound of formula (A1) which is then selectively deprotected to give the compound of formula (A),
- R is an appropriate protective group known to those skilled in the art.
- the protective group is chosen from triarylmethyls and / or silyls.
- triarylmethyl include trityl, monomethoxytrityl, 4,4'-dimethoxytrityl and 4,4 ', 4 "-trimethoxytrityl.
- silyl groups include trimethylsilyl, tert-butyldimethylsilyl, triisopropylsilyl, tert-. butyldiphenylsilyl, tri-iso-propylsilyloxymethyl and [2- (trimethylsilyl) ethoxy] methyl.
- any hydroxyl group attached to the pentose is protected by an appropriate protective group known to those skilled in the art.
- protecting groups fall within the competence of those skilled in the art.
- Protecting groups can also be removed by methods well known to those skilled in the art, for example, with an acid (eg, an inorganic or organic acid), a base or a source of fluoride.
- the nitrogenous derivative of formula (E) is coupled to the pentose of formula (D) by a reaction in the presence of a Lewis acid resulting in the compound of formula (Al).
- Lewis acids include TMSOTf, BF 3 .0Et 2 , T1Cl4 and
- the present invention relates to a method for preparing compounds of formula I-A, I-C, I-E, I-G.
- the nicotinamide of formula E is coupled to the ribose tetraacetate of formula D by a coupling reaction in the presence of a Lewis acid, resulting in the compound of formula A-1:
- a step of reducing the compound of formula I-A is carried out, resulting in the compound of formula I-E.
- the compound of formula I-E is then mono-phosphorylated as described in the fourth step and hydrolyzed to yield the compound of formula I-G.
- the compounds of formula (I) are selected from compounds 1-A to 1-J of the table below:
- the compounds of the invention are the compounds of formula I-A, I-C, I-E and I-G from the table above or a pharmaceutically acceptable salt and / or solvate thereof.
- the compound is the compound of formula 1-C or 1-D, a pharmaceutically acceptable salt and / or solvate thereof.
- the synthesis can comprise the phosphorylation of alpha-nicotinamide riboside, in the presence of phosphorus chloride and of a trialkyl phosphate, to obtain a phosphorodichloridate:
- the compound according to the invention can be prepared by activating compound IB by the addition of carbonyldiimidazole (CDI):
- alpha-nicotinamide riboside is added as follows:
- a compound of formula I comprising three phosphate groups can be prepared as follows.
- Compound IB can be prepared by the addition of carbonyldiimidazole (CDI):
- the invention relates to a method for preparing the compound of formula I described above.
- the method firstly consists in mono-phosphorylating a compound of formula X, in the presence of phosphoryl chloride in a trialkyl phosphate, to obtain the phophorodichloridate compound XI,
- the phosphate compound of formula XII obtained in the second step is then reacted with a phophorodichloridate compound of formula XIII obtained as described in the first step,
- the process further comprises a step of reducing the compound of formula la, using various methods known to specialists, to give the compound of formula la, where Y'i and Y ' 2 are identical. and each represent CH 2 and where X'i, X ' 2 , R'i, R' 2 , R's, R ' 4 , R'S, R' s, R'7, R 's, R' 9, R '10 , R '11, R' 12, R '13, R' 14, Y ', Y' 2, and - are as described herein for formula Ia.
- R is a suitable protecting group known to those skilled in the art.
- suitable protecting groups are triarylmethyl and / or silyl groups.
- triarylmethyl include trityl, monomethoxytrityl, 4,4'-dimethoxytrityl and 4,4 ', 4 "-trimethoxytrityl.
- silyl groups include trimethylsilyl, tert-butyldimethylsilyl, triisopropylsilyl. , tert-butyldiphenylsilyl, tri-iso-propylsilyloxymethyl and [2- (trimethylsilyl) ethoxy] methyl.
- any hydroxy group attached to the pentose ring is protected by an appropriate protection group known to specialists in this art.
- protection groups fall within the competence of those who are competent in this field. Any protecting group can also be removed by methods known in the art, for example, with an acid (eg, a mineral or an organic acid), a base or a source of fluoride.
- an acid eg, a mineral or an organic acid
- a base e.g., a base or a source of fluoride.
- the nitrogenous derivatives of formula XV are added to pentose XIV by a coupling reaction in the presence of a Lewis acid to give the compound of formula X-1.
- suitable Lewis acids include TMSOTf, BF3.0Et2, TiCl4 and FeCl3.
- the invention relates to a method for preparing the compound of formula VIII,
- the nicotinamide of formula XV is added to ribose tetraacetate XIV, by a coupling reaction in the presence of a Lewis acid, to give the compound of formula X-1:
- a fourth step the phophorodichloridate compound XI obtained in the third step is partially hydrolyzed to give the phosphate compound of formula XII:
- a fifth step the phosphate compound of formula XII obtained in the fourth step is then reacted with the phophorodichloridate compound of formula XI obtained as described in the third step, to obtain the compound of formula VIII.
- the invention relates to a method for preparing the compound of formula IX,
- the compound of formula IX is obtained from the compound of formula VIII, previously synthesized as described above.
- the compound of formula IX is obtained by reducing the compound of formula VIII, using a suitable reducing agent known to those skilled in the art, to give the compound of formula IX.
- the preferred compounds of the invention are compounds la-A to la-1, listed in Table 2:
- Figure 1 is a graph showing the evolution of weight gain (Figure IA) and water consumption (Figure IB) among groups 1 to 4.
- FIG. 2 is a graph showing the evolution of the weight and size of the thymus among groups 1 to 4.
- Figure 3 is a graph showing the number of thymocytes among groups 1 to 4.
- FIG. 4A is a graph showing the number of B cells in the bone marrow taken from mice, among groups 1 to 4.
- FIG. 4B is a graph showing the number of CD38 + B cells in the bone marrow taken from mice, among groups 1 to 4.
- FIG. 5A is a graph showing the number of CD45 + B cells in the bone marrow taken from mice, among groups 1 to 4.
- FIG. 5B is a graph showing the number of pre-pro-B cells in the bone marrow taken from mice, among groups 1 to 4.
- FIG. 5C is a graph showing the number of pro-B cells in the bone marrow taken from mice, among groups 1 to 4.
- FIG. 5D is a graph showing the number of pre-B cells in the bone marrow taken from mice, among groups 1 to 4.
- FIG. 5E is a graph showing the number of immature B cells in the bone marrow taken from mice, among groups 1 to 4.
- FIG. 6A is a graph showing the number of CD45 + B cells in the spleen taken from mice, among groups 1 to 4.
- FIG. 6B is a graph showing the number of activated B cells in the spleen taken from mice, among groups 1 to 4.
- FIG. 6C is a graph showing the number of memory B cells in the spleen taken from mice, among groups 1 to 4.
- Fig. 6D is a graph showing the number of germinal B cells in the spleen taken from mice, among groups 1 to 4.
- FIG. 6E is a graph showing the number of plasma B cells in the spleen taken from mice, among groups 1 to 4.
- FIG. 7A is a graph showing the number of CD4 + T cells in the spleen taken from mice, among groups 1 to 4.
- Fig. 7B is a graph showing the number of CD4 + memory T cells in the spleen taken from mice, among groups 1 to 4.
- FIG. 8A is a graph showing the number of naive CD8 + T cells in the spleen taken from mice, among groups 1 to 3.
- Fig. 8B is a graph showing the number of effector CD8 + T cells in the spleen taken from mice, among groups 1 to 3.
- FIG. 8C is a graph showing the number of CD8 + memory effector T cells in the spleen taken from mice, among groups 1 to 3.
- Figure 8D is a graph showing the number of CD8 + memory T cells in the spleen taken from mice, among groups 1 to 3.
- Fig. 9A is a graph showing the percentage of proliferation of CD4 + T cells, relative to unstimulated cells, among groups 1 to 4.
- FIG. 9B is a graph showing the percentage of proliferation of CD8 + T cells, relative to unstimulated cells, among groups 1 to 4.
- FIG. 10A is a graph showing the percentage of CD4 + T cells, stimulated and not stimulated by beads coated with anti-CD3 / CD28 antibodies, producing gamma interferon (IFN ⁇ ) among groups 1 to 4.
- IFN ⁇ gamma interferon
- FIG. 10B is a graph showing the percentage of CD4 + T cells, stimulated and unstimulated by beads coated with anti-CD3 / CD28 antibodies, producing interleukin 10 (IL10) among groups 1 to 4.
- IL10 interleukin 10
- mice 58 The solution is used at room temperature for a maximum of 2 days and freshly prepared for each new administration. The mice are weighed weekly to adjust the dose of the compound to be administered. Throughout the phase, a standard diet and tap water will be provided ad libitum.
- the study comprises 4 groups of 6 mice each:
- Group 1 young mice (10 weeks old) + drinking water (vehicle)
- Group 2 old mice (15 months old) + drinking water (vehicle)
- Group 3 old mice (15 months old) + compound l-B (alpha-NMN) in drinking water
- Group 4 old mice (15 months old) + compound l-A (beta-NMN) in drinking water
- mice The water consumption of the mice is evaluated per cage, every two days. The mice are weighed weekly. Group 3 mice are sacrificed after 4 weeks for organ collection and characterization of T cell function. Group 4 mice are sacrificed after 6 weeks for organ collection and characterization of T cell function. On the day of sacrifice, the mice are anesthetized with Vetoflurane (isoflurane) and blood is drawn from the retorbital sinuses. The blood is incubated for 30 minutes at room temperature, then centrifuged at 1300 g for 10 minutes.
- Vetoflurane isoflurane
- the spleen, thymus and bone marrow of each animal is removed.
- the thymus is weighed and measured to assess its involution.
- photos of the thymus are taken on 5 animals per group.
- the thymus is divided into two parts; a part is treated with formalin for a histological study. The second part is treated for the characterization of immune cells.
- the thymus and the spleen are crushed on a sieve of 40 cells / ⁇ m on a 50 ml tube with a syringe plunger.
- the bone marrow is rinsed with RPMI culture medium using a needle and syringe.
- the cell suspension is then centrifuged at 400 g for 5 minutes at 4 ° C. Lysis of red blood cells is also performed before cell counting and use for cytometry.
- the cells isolated from the spleen, thymus and bone marrow will be labeled with antibodies according to the following panels to identify the proportion of naive, effector and memory T and B cells.
- Proliferation Assay LAO + 5 weeks, splenocytes were labeled with 2.5 mM of CFSE and then cultured at a concentration of 0,25.10 e cells per well in a 96 well plate. The cells are stimulated with 2.5 ⁇ g of InfluvacTetra ® and incubated at 37 ° C. for 96 hours. The cells are then labeled with anti-CD4 and CD8 antibodies and the proliferation of CD4 + and CD8 + T cells is analyzed by flow cytometry.
- the size of the thymus is reduced considerably and significantly in old mice (group 2) compared to young mice (group 1), which reflects an involution of the thymus. Involution of the thymus with age is observed in humans and validates the model.
- the administration of alpha-NMN did not increase the volume or size of the thymus compared to elderly untreated mice.
- the administration of b-NMN makes it possible to increase the size of the thymus significantly compared to the mice of groups 2 and 3 to a level close to that of the young mice of group 1.
- the number of B cells decreases significantly in old mice (group 2) compared to young mice (group 1) in the bone marrow.
- the administration of a-NMN (group 3) and b-NMN (group 4) significantly increases the number of B cells and restores a level identical or almost identical to that observed in young mice.
- Figure 4A As for CD38 + cells, the level of these cells is reduced in old mice (group 2) compared to young mice (group 1).
- the administration of a-NMN (group 3) and b-NMN (group 4) makes it possible to restore the quantity of CD38 + B cells to the level of that expressed by the young mice of group 1 (FIG. 4B).
- the level of B cells is significantly reduced in the old mice of group 2 compared to the young mice of group 1.
- the administration of a-NMN and b- NMN makes it possible to significantly increase the number of CD45 + B cells to levels even higher than that expressed in group 1 mice (see FIG. 5A).
- Administration of a-NMN and b-NMN also increases the number of pre-pro-B cells (Figure 5B) but has not shown any influence on the number of pro-B cells ( Figure 5C).
- the administration of a-NMN (group 3) and of b-NMN (group 4) makes it possible to increase the number of pre-B cells (FIG. 5D) and of immature B cells (FIG. 5E).
- the B cells present in the spleen of the mice of each of the groups were characterized. As shown in Figure 6A, the number of CD45 + T cells in the spleen was significantly increased by the administration of b-NMN (group 4) compared to other groups of mice. The administration of b-NMN also increases the number of activated B cells in the spleen significantly compared to other groups (Figure 6B), as well as memory B cells (Figure 6C) and germinal B cells ( figure 6D). The number of plasma cells is not changed among the 4 study groups (FIG. 6E).
- the CD4 + T cells present in the spleen of the mice of each of the groups were characterized. As shown in Figure 7A, the total number of CD4 + T cells in the spleen is significantly increased by the administration of b-NMN (group 4) compared to other groups of mice. The administration of b-NMN also makes it possible to increase the memory T cells significantly compared to the other groups (FIG. 7B). Administration of a-NMN and b-NMN also increases the number of CD4 + effector T cells compared to group 3.
- the total splenocytes were stimulated with beads coated with anti-CD3 / CD28 for 18 h. As shown in Figures 10A and 10B, aging reduced the proportion of IFN ⁇ and IL10 producing cells upon stimulation with anti-CD3 / CD28 coated beads. For ⁇ -IFN ( Figure 10A), the response to stimulation was lower in elderly mice treated with vehicle or ⁇ -NMN and an absence of response in the b-NMN group was observed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2005739A FR3110836B1 (en) | 2020-05-29 | 2020-05-29 | Use of NMN to reduce immunosuppression and immunosenescence |
PCT/EP2021/064121 WO2021239850A1 (en) | 2020-05-29 | 2021-05-26 | Use of nmn to reduce immunodepression and immunosenescence |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4157284A1 true EP4157284A1 (en) | 2023-04-05 |
Family
ID=72885637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21728902.4A Withdrawn EP4157284A1 (en) | 2020-05-29 | 2021-05-26 | Use of nmn to reduce immunodepression and immunosenescence |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230136569A1 (en) |
EP (1) | EP4157284A1 (en) |
CN (1) | CN115968294A (en) |
FR (1) | FR3110836B1 (en) |
WO (1) | WO2021239850A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104814974A (en) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products |
DK3331894T3 (en) | 2015-08-05 | 2021-03-22 | Metro Int Biotech Llc | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USES THEREOF |
GB2542881B (en) * | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
WO2017079195A1 (en) | 2015-11-02 | 2017-05-11 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
US10722529B2 (en) * | 2015-12-03 | 2020-07-28 | Temple University—Of the Commonwealth System of Higher Education | Modulation of NAD+ metabolic pathways for treatment of disease |
JP2021524863A (en) * | 2018-05-15 | 2021-09-16 | ジャンプスタート ファーティリティ ピーティーワイ リミテッド | Inorganic salt of nicotinic acid mononucleotide as an anti-aging agent |
JP2022523864A (en) * | 2019-03-22 | 2022-04-26 | メトロ インターナショナル バイオテック,エルエルシー | Compositions Containing Phosphorus Derivatives of Nicotinamide Riboside and Methods for Modulation of Nicotinamide Adenine Dinucleotide |
US10618927B1 (en) * | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
-
2020
- 2020-05-29 FR FR2005739A patent/FR3110836B1/en active Active
-
2021
- 2021-05-26 WO PCT/EP2021/064121 patent/WO2021239850A1/en unknown
- 2021-05-26 CN CN202180041663.6A patent/CN115968294A/en active Pending
- 2021-05-26 US US17/927,478 patent/US20230136569A1/en active Pending
- 2021-05-26 EP EP21728902.4A patent/EP4157284A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
FR3110836B1 (en) | 2023-06-16 |
WO2021239850A1 (en) | 2021-12-02 |
US20230136569A1 (en) | 2023-05-04 |
FR3110836A1 (en) | 2021-12-03 |
CN115968294A (en) | 2023-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1268335C (en) | Nucleoside analogs with carboxamidine wodified monocyclic base | |
CH664974A5 (en) | PRODUCTION OF THE TARGET CELL LYSE FACTOR. | |
EP1625850A1 (en) | Immunostimulant | |
CN116761606A (en) | Pharmaceutical composition for enhancing cell killing and application thereof | |
DE69534745T2 (en) | IMMUNOPOTENZATING 5'-NUCLEOTIDASE RESISTANT INOSINMONOPHOSPHATE DERIVATIVES AND THEIR USE | |
JP2634218B2 (en) | Compositions for enhancing ADCC therapy | |
CN1289594A (en) | Method for treatment of diseases concerned with cytoplasmic factor | |
WO2008068429A2 (en) | Composition for the prevention and/or treatment of diseases associated with tnf and/or il-12 overexpression | |
EP4157284A1 (en) | Use of nmn to reduce immunodepression and immunosenescence | |
RU2211698C2 (en) | Modulation of immune response due to ribavirin | |
EP4045058A1 (en) | Use of nicotinamide mononucleotide (nmn) for the prevention and/or treatment of rheumatoid arthritis, and corresponding compositions | |
EP0819136B1 (en) | Mdp derivatives and conjugates having haematopoietic function stimulating activity, and compositions containing same | |
WO2020234830A1 (en) | Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release | |
TW202019440A (en) | Combination therapy for treating cancer | |
US20100256230A1 (en) | 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof | |
WO2021105461A1 (en) | Use of compounds for the prevention and/or treatment of ankylosing spondylitis, and corresponding compositions | |
WO2024011264A1 (en) | Combination immunoresponse regulator/immunotherapy system and method | |
CN117982658A (en) | Application of ENPP1 inhibitor and extracellular nucleotidase inhibitor in synergistic inhibition of tumor | |
RU2292892C2 (en) | Immunomodulating medicament (variants) | |
CN1494912A (en) | Method for curing diseases related to cell factor | |
CN1817349A (en) | Nucleoside analogues with carboxamidine-modified monocyclic base | |
KR20050103157A (en) | Medicament improving the immune action of interferon-gamma, and immune-enhancing composition comprising interferon-gamma and the medicament | |
CN1946735A (en) | Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221216 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230725 |